Patents by Inventor Laising Yen

Laising Yen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200048716
    Abstract: MiniVectors and compositions containing MiniVectors that target ovarian cancer genes selected from FOXM1, AKT, CENPA, PLK1, CDC20, BIRC5, AURKB, CCNB1, CDKN3, BCAM-AKT2, CDKN2D-WDFY2, SLC25A6, CIP2A, CD133, ALDH1A1, CD44, SALL4, and/or PRDM16, alone or in any combination, are provided, along with uses in the treatment of ovarian cancer.
    Type: Application
    Filed: November 5, 2018
    Publication date: February 13, 2020
    Inventors: E. Lynn Zechiedrich, Martin M. Matzuk, Laising Yen, Zhifeng Yu, Lirio Milenka Arevalo-Soliz, Daniel James Catanese, JR., Jonathan Marcus Fogg, Christopher Elbert Coker
  • Publication number: 20190330633
    Abstract: Embodiments of the disclosure include compositions and methods for generating RNA nanostructures, particularly in a cell. In particular embodiments, RNA subunits comprising at least one three-way junction and at least one kissing loop are configured such that multiple RNA subunits can polymerize into a specific structure. In particular embodiments, the RNA subunits are configured such that sequence of at least one kissing loop is complementary to sequence of another kissing loop, such as on another RNA subunit, and the summation of multiple RNA subunits having specific individual structures results in a combined polymerized structure of a defined shape. In specific embodiments, an RNA nanostructure generated from methods herein is utilized for an application, such as manufacturing or genetic modifications in a cell.
    Type: Application
    Filed: November 10, 2017
    Publication date: October 31, 2019
    Inventor: Laising Yen
  • Patent number: 10233447
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: March 19, 2019
    Assignee: The Children's Medical Center Corporation
    Inventors: Richard Mulligan, Laising Yen
  • Publication number: 20180327747
    Abstract: Embodiments of the disclosure concern the use of expression constructs in which at least one polyA signal is embedded upstream of an expressible transcript, such as within a 5? UTR for the transcript, for example. In certain embodiments, the polyA signal is comprised within a ligand-binding aptamer, and the binding of the ligand to the aptamer, or lack thereof, dictates the outcome for the expressible transcript. In specific embodiments, absence of the ligand causes the expressed transcript having a polyA in its 5? UTR to be expressed but then degraded, whereas presence of the ligand causes inhibition of degradation upon expression of the expressible transcript. More than one ligand-binding aptamer may be present on the same expression construct.
    Type: Application
    Filed: November 11, 2016
    Publication date: November 15, 2018
    Inventors: Laising Yen, Liming Luo, Pei-Wen Chao
  • Publication number: 20170253872
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.
    Type: Application
    Filed: January 3, 2017
    Publication date: September 7, 2017
    Applicant: The Children s Medical Center Corporation
    Inventors: Richard Mulligan, Laising Yen
  • Publication number: 20160340743
    Abstract: Embodiments of the disclosure include methods and compositions associated with CDKN2D-WDFY2 chimeric RNA, the fusion gene that produces the chimeric RNA, and polypeptides produced from the chimeric RNA. In particular embodiments, the chimeric RNA is useful for methods of treatment, diagnosis, and/or prognosis as they relate to ovarian cancer, or therapy therefor, including at least high-grade serous carcinoma.
    Type: Application
    Filed: February 10, 2015
    Publication date: November 24, 2016
    Inventors: Laising Yen, Kalpana Kannan
  • Publication number: 20150056174
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.
    Type: Application
    Filed: May 14, 2012
    Publication date: February 26, 2015
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Richard Mulligan, Laising Yen
  • Publication number: 20110061120
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.
    Type: Application
    Filed: March 1, 2010
    Publication date: March 10, 2011
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Richard Mulligan, Laising Yen
  • Publication number: 20050158741
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.
    Type: Application
    Filed: November 15, 2004
    Publication date: July 21, 2005
    Applicant: Children's Hospital
    Inventors: Richard Mulligan, Laising Yen